Pediatric intensive care patients Continuous renal replacement therapy Continuous renal replacement therapy Children
Conditions
Interventions
Performing CRRT using citrate solution (Prismocitrate) as regional anticoagulant, targeting circuit ionized calcium level 1-1.5 mg/dl.,Performing CRRT using unfractionated heparin as anticoagulant, ta
Experimental Drug,Active Comparator Drug
Citrate,Heparin
Sponsors
Suvikrom Law
Eligibility
Sex/Gender
All
Age
1 Years to 18 Years
Inclusion criteria
Inclusion criteria: 1. Children aged 1-18 years who are admitted to PICU, 2. Plan to receive continuous renal replacement therapy
Exclusion criteria
Exclusion criteria: 1. Coagulopathy (INR >/= 2), 2. Platelet < 50000/mm3, 3. Heparin induced thrombocytopenia (HIT) or history of HIT, 4. Active bleeding, 5. Receiving heparin or low molecular weight heparin in therapeutic dose, 6. Pregnancy or lactation, 7. Heparin allergy, 8. Serum lactate > 5 mmol/l, 9. On ECMO
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Circuit life During CRRT treatment Time from starting CRRT circuit until stop due to circuit clotting, measured in minutes | — |
Secondary
| Measure | Time frame |
|---|---|
| Citrate accumulation Measured every 6 hours during CRRT Total/ionized Ca ratio more than 2.5,Metabolic alkalosis Measured every 6 hours during CRRT pH above 7.50 and HCO3 above 30,Bleeding During CRRT treatment Direct observation,Heparin induced thrombocytopenia During CRRT treatment Platelet count and antibody | — |
Countries
Thailand
Contacts
Public ContactSuvikrom Law
Faculty of Medicine Siriraj Hospital, Mahidol University
Outcome results
None listed